Edition:
India

Cara Therapeutics Inc (CARA.OQ)

CARA.OQ on NASDAQ Stock Exchange Global Market

21.16USD
15 Nov 2019
Change (% chg)

-- (--)
Prev Close
$21.16
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
227,019
52-wk High
$27.50
52-wk Low
$12.20

Latest Key Developments (Source: Significant Developments)

Cara Therapeutics Announces Publication Of Difelikefalin KALM-1 Phase 3 Trial Results
Monday, 11 Nov 2019 

Nov 11 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS ANNOUNCES PUBLICATION OF DIFELIKEFALIN (KORSUVA™ INJECTION) KALM™-1 PHASE 3 TRIAL RESULTS IN THE NEW ENGLAND JOURNAL OF MEDICINE.CARA THERAPEUTICS ANNOUNCES PUBLICATION OF DIFELIKEFALIN (KORSUVA™ INJECTION) KALM™-1 PHASE 3 TRIAL RESULTS IN THE NEW ENGLAND JOURNAL OF MEDICINE.CARA THERAPEUTICS INC - TREATMENT WITH KORSUVA INJECTION RESULTED IN STATISTICALLY SIGNIFICANT REDUCTION IN PRURITUS INTENSITY.CARA THERAPEUTICS INC - TREATMENT WITH KORSUVA RESULTED IN IMPROVEMENT IN ITCH-RELATED QUALITY OF LIFE MEASURES FOR BOTH PRIMARY, SECONDARY ENDPOINTS.  Full Article

Cara Therapeutics Inc Reports Q3 Loss Per Share Of $0.74
Wednesday, 6 Nov 2019 

Nov 5 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.74.Q3 REVENUE $5.8 MILLION.Q3 REVENUE ESTIMATE $4.3 MILLION -- REFINITIV IBES DATA.Q3 EARNINGS PER SHARE ESTIMATE $-0.58 -- REFINITIV IBES DATA.CARA THERAPEUTICS - AT SEPTEMBER 30, 2019, CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $249.1 MILLION VERSUS $182.8 MILLION AT DECEMBER 31, 2018.CARA THERAPEUTICS -SEES EXISTING CASH, CASH EQUIVALENTS AND AVAILABLE-FOR-SALE MARKETABLE SECURITIES AS OF SEPT 30, TO FUND CO INTO SECOND HALF 2021.  Full Article

Cara Therapeutics Announces Completion Of Interim Statistical Assessment And Small Increase In Target Enrollment For KALM-2 Phase 3 Global Trial Of KORSUVA Injection In Hemodialysis Patients Wit
Monday, 14 Oct 2019 

Oct 14 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS ANNOUNCES COMPLETION OF INTERIM STATISTICAL ASSESSMENT AND SMALL INCREASE IN TARGET ENROLLMENT FOR KALM-2 PHASE 3 GLOBAL TRIAL OF KORSUVA™ INJECTION IN HEMODIALYSIS PATIENTS WITH PRURITUS.CARA THERAPEUTICS ANNOUNCES COMPLETION OF INTERIM STATISTICAL ASSESSMENT AND SMALL INCREASE IN TARGET ENROLLMENT FOR KALM-2 PHASE 3 GLOBAL TRIAL OF KORSUVA™ INJECTION IN HEMODIALYSIS PATIENTS WITH PRURITUS.CARA THERAPEUTICS INC - FULL TRIAL ENROLLMENT EXPECTED IN Q4 OF 2019.CARA THERAPEUTICS INC - PATIENT ENROLLMENT INCREASED APPROXIMATELY 20% TO MAINTAIN GREATER THAN 90% STATISTICAL POWER.CARA THERAPEUTICS - REMAIN ON TRACK TO FILE NDA FOR KORSUVA INJECTION IN SECOND HALF OF 2020.  Full Article

Cara Therapeutics Announces Pricing Of $126.5 Mln Offering Of Common Stock
Thursday, 25 Jul 2019 

July 24 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS ANNOUNCES PRICING OF $126.5 MILLION OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 5.50 MILLION COMMON SHARES PRICED AT $23.00PER SHARE.  Full Article

Cara Therapeutics Says Commenced An Underwritten Public Offering Of 5 Mln Shares
Thursday, 25 Jul 2019 

July 24 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.CARA THERAPEUTICS INC - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF 5 MILLION SHARES OF ITS COMMON STOCK.  Full Article

Cara Therapeutics Results From Phase 3 Trial Of Korsuva In Hemodialysis Patients With Pruritus
Wednesday, 29 May 2019 

May 29 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM KALM-1 PIVOTAL PHASE 3 TRIAL OF KORSUVA™ INJECTION IN HEMODIALYSIS PATIENTS WITH PRURITUS.CARA THERAPEUTICS INC - STATISTICALLY SIGNIFICANT IMPROVEMENT IN PRIMARY ENDPOINT.CARA THERAPEUTICS INC - KORSUVA INJECTION WELL-TOLERATED THROUGH 12 WEEKS OF TREATMENT.CARA THERAPEUTICS INC - KORSUVA INJECTION WELL-TOLERATED THROUGH 12 WEEKS OF TREATMENT -.CARA THERAPEUTICS INC - KORSUVA INJECTION WELL-TOLERATED THROUGH 12 WEEKS OF TREATMENT.CARA THERAPEUTICS INC - KORSUVA INJECTION WELL-TOLERATED THROUGH 12 WEEKS OF TREATMENT.CARA THERAPEUTICS INC - OVERALL, INCIDENCE OF ADVERSE EVENTS & SERIOUS AES WERE SIMILAR ACROSS BOTH KORSUVA & PLACEBO GROUPS.CARA THERAPEUTICS INC - OVERALL, INCIDENCE OF ADVERSE EVENTS (AES) AND SERIOUS AES WERE SIMILAR ACROSS BOTH KORSUVA AND PLACEBO GROUPS.  Full Article

Cara Therapeutics Q3 Loss Per Share $0.51
Wednesday, 7 Nov 2018 

Nov 6 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.51.Q3 EARNINGS PER SHARE VIEW $-0.50 -- THOMSON REUTERS I/B/E/S.RECOGNIZED $5.0 MILLION OF LICENSE AND MILESTONE FEE REVENUE DURING Q3 OF 2018.AT SEPTEMBER 30, 2018, CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $206.1 MILLION.  Full Article

Cara Therapeutics And Vifor Fresenius Medical Care Renal Pharma Enter Into Ex-U.S. Licensing Agreement
Wednesday, 23 May 2018 

May 23 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS AND VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA (VFMCRP) ENTER INTO EX-U.S. LICENSING AGREEMENT TO COMMERCIALIZE KORSUVA™ INJECTION IN DIALYSIS PATIENTS WITH PRURITUS.CARA THERAPEUTICS INC - CARA ELIGIBLE FOR UP TO $470 MILLION IN REGULATORY AND COMMERCIAL MILESTONES.CARA THERAPEUTICS INC - VFMCRP TO COMMERCIALIZE KORSUVA INJECTION WORLDWIDE EXCEPT IN U.S., JAPAN AND SOUTH KOREA.CARA THERAPEUTICS INC - CARA RECEIVES UPFRONT PAYMENT OF $50 MILLION IN CASH AND AN EQUITY INVESTMENT OF $20 MILLION.CARA THERAPEUTICS INC - CARA IS ELIGIBLE TO RECEIVE TIERED ROYALTIES BASED ON NET SALES OF KORSUVA INJECTION IN LICENSED TERRITORIES.CARA THERAPEUTICS INC - CARA WILL SOLELY PROMOTE KORSUVA INJECTION IN ALL NON-FMC CLINICS IN U.S. AND RETAIN ALL PROFITS FROM THOSE SALES.  Full Article

Cara Therapeutics Reports Q4 Loss Per Share $0.43
Friday, 16 Mar 2018 

March 15 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.43.Q4 EARNINGS PER SHARE VIEW $-0.40 -- THOMSON REUTERS I/B/E/S.‍COMPANY DID NOT RECOGNIZE ANY REVENUES DURING Q4 OF 2017 OR 2016​.  Full Article